Wells Fargo & Company Issues Pessimistic Forecast for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its target price decreased by research analysts at Wells Fargo & Company from $1.50 to $1.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price would suggest a potential upside […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its target price decreased by research analysts at Wells Fargo & Company from $1.50 to $1.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price would suggest a potential upside […]
